Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care

Subodh Verma; Eric Klug; Viacheslav Y. Mareev; Zhanna D. Kobalava; Kim A. Connelly; Mustafa Arici; Otávio Berwanger; Anwar Santoso; Roopa Mehta; Gus Meglis; Mikhail N. Kosiborod

doi:10.1097/HCO.0000000000000774

Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care

Subodh Verma, Eric Klug, Viacheslav Y. Mareev, Zhanna D. Kobalava, Kim A. Connelly, Mustafa Arici, Otávio Berwanger, Anwar Santoso, Roopa Mehta, Gus Meglis, Mikhail N. Kosiborod

Department of Cardiology and Vascular Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.

Original language	English
Pages (from-to)	589-601
Number of pages	13
Journal	Current Opinion in Cardiology
Volume	35
Issue number	5
DOIs	https://doi.org/10.1097/HCO.0000000000000774
Publication status	Published - 1 Sep 2020

Access to Document

10.1097/HCO.0000000000000774

Fingerprint Dive into the research topics of 'Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care'. Together they form a unique fingerprint.

Cite this

Verma, S., Klug, E., Mareev, V. Y., Kobalava, Z. D., Connelly, K. A., Arici, M., Berwanger, O., Santoso, A., Mehta, R., Meglis, G., & Kosiborod, M. N. (2020). Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care. Current Opinion in Cardiology, 35(5), 589-601. https://doi.org/10.1097/HCO.0000000000000774

Verma, Subodh ; Klug, Eric ; Mareev, Viacheslav Y. ; Kobalava, Zhanna D. ; Connelly, Kim A. ; Arici, Mustafa ; Berwanger, Otávio ; Santoso, Anwar ; Mehta, Roopa ; Meglis, Gus ; Kosiborod, Mikhail N. / Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care : an integrated and multidisciplinary approach to patient-centered care. In: Current Opinion in Cardiology. 2020 ; Vol. 35, No. 5. pp. 589-601.

@article{93329dc1851f48d7a742198bfc758d8e,

title = "Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care",

abstract = "PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.",

author = "Subodh Verma and Eric Klug and Mareev, {Viacheslav Y.} and Kobalava, {Zhanna D.} and Connelly, {Kim A.} and Mustafa Arici and Ot{\'a}vio Berwanger and Anwar Santoso and Roopa Mehta and Gus Meglis and Kosiborod, {Mikhail N.}",

year = "2020",

month = sep,

day = "1",

doi = "10.1097/HCO.0000000000000774",

language = "English",

volume = "35",

pages = "589--601",

journal = "Current Opinion in Cardiology",

issn = "0268-4705",

publisher = "Lippincott Williams and Wilkins Ltd.",

number = "5",

}

Verma, S, Klug, E, Mareev, VY, Kobalava, ZD, Connelly, KA, Arici, M, Berwanger, O, Santoso, A, Mehta, R, Meglis, G & Kosiborod, MN 2020, 'Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care', Current Opinion in Cardiology, vol. 35, no. 5, pp. 589-601. https://doi.org/10.1097/HCO.0000000000000774

Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care : an integrated and multidisciplinary approach to patient-centered care. / Verma, Subodh; Klug, Eric; Mareev, Viacheslav Y.; Kobalava, Zhanna D.; Connelly, Kim A.; Arici, Mustafa; Berwanger, Otávio; Santoso, Anwar; Mehta, Roopa; Meglis, Gus; Kosiborod, Mikhail N.

In: Current Opinion in Cardiology, Vol. 35, No. 5, 01.09.2020, p. 589-601.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care

T2 - an integrated and multidisciplinary approach to patient-centered care

AU - Verma, Subodh

AU - Klug, Eric

AU - Mareev, Viacheslav Y.

AU - Kobalava, Zhanna D.

AU - Connelly, Kim A.

AU - Arici, Mustafa

AU - Berwanger, Otávio

AU - Santoso, Anwar

AU - Mehta, Roopa

AU - Meglis, Gus

AU - Kosiborod, Mikhail N.

PY - 2020/9/1

Y1 - 2020/9/1

N2 - PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.

AB - PURPOSE OF REVIEW: The management of individuals who live with type 2 diabetes requires an integrated and multifaceted approach. RECENT FINDINGS: Sodium-glucose cotransporter 2 inhibitors effectively prevent and treat cardiorenal complications in the presence of type 2 diabetes. They also reduce death and disease progression in those with established heart failure (with reduced ejection fraction) in the absence of diabetes. SUMMARY: Close collaborations between primary care physicians, cardiovascular specialists, endocrinologists and nephrologists are necessary to optimize cardiovascular, renal and metabolic risk reduction in their shared patients.

UR - http://www.scopus.com/inward/record.url?scp=85089301163&partnerID=8YFLogxK

U2 - 10.1097/HCO.0000000000000774

DO - 10.1097/HCO.0000000000000774

M3 - Article

C2 - 32694262

AN - SCOPUS:85089301163

VL - 35

SP - 589

EP - 601

JO - Current Opinion in Cardiology

JF - Current Opinion in Cardiology

SN - 0268-4705

IS - 5

ER -

Sodium-glucose cotransporter 2 inhibitors at the intersection of cardiovascular, renal and metabolic care: an integrated and multidisciplinary approach to patient-centered care

Abstract

Access to Document

Other files and links

Cite this